Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Cash from Financing Activities (2024 - 2025)

Kairos Pharma's Cash from Financing Activities history spans 2 years, with the latest figure at $223000.0 for Q2 2025.

  • For Q2 2025, Cash from Financing Activities rose 49.66% year-over-year to $223000.0; the TTM value through Jun 2025 reached $8.4 million, changed N/A, while the annual FY2025 figure was $6.7 million, 29.72% up from the prior year.
  • Cash from Financing Activities reached $223000.0 in Q2 2025 per KAPA's latest filing, down from $3.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $5.2 million in Q3 2024 to a low of -$142000.0 in Q4 2024.